Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer
Overview
Authors
Affiliations
The ability of disseminated cancer cells to evade the immune response is a critical step for efficient metastatic progression. Protection against an immune attack is often provided by the tumor microenvironment that suppresses and excludes cytotoxic CD8 T cells. Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive metastatic disease with unmet needs, yet the immunoprotective role of the metastatic tumor microenvironment in pancreatic cancer is not completely understood. In this study, we find that macrophage-derived granulin contributes to cytotoxic CD8 T-cell exclusion in metastatic livers. Granulin expression by macrophages was induced in response to colony-stimulating factor 1. Genetic depletion of granulin reduced the formation of a fibrotic stroma, thereby allowing T-cell entry at the metastatic site. Although metastatic PDAC tumors are largely resistant to anti-PD-1 therapy, blockade of PD-1 in granulin-depleted tumors restored the antitumor immune defense and dramatically decreased metastatic tumor burden. These findings suggest that targeting granulin may serve as a potential therapeutic strategy to restore CD8 T-cell infiltration in metastatic PDAC, thereby converting PDAC metastatic tumors, which are refractory to immune checkpoint inhibitors, into tumors that respond to immune checkpoint inhibition therapies. These findings uncover a mechanism by which metastatic PDAC tumors evade the immune response and provide the rationale for targeting granulin in combination with immune checkpoint inhibitors for the treatment of metastatic PDAC. http://cancerres.aacrjournals.org/content/canres/78/15/4253/F1.large.jpg .
A stumbling block in pancreatic cancer treatment: drug resistance signaling networks.
Liu J, Zhang B, Huang B, Zhang K, Guo F, Wang Z Front Cell Dev Biol. 2025; 12:1462808.
PMID: 39872846 PMC: 11770040. DOI: 10.3389/fcell.2024.1462808.
Klein L, Tu M, Krebs N, Urbach L, Grimm D, Latif M Nat Commun. 2025; 16(1):335.
PMID: 39762215 PMC: 11704331. DOI: 10.1038/s41467-024-55330-7.
Wang Q, Wang J, Xu K, Luo Z Front Immunol. 2024; 15:1481247.
PMID: 39416792 PMC: 11479911. DOI: 10.3389/fimmu.2024.1481247.
Bai Y, Chi K, Zhao D, Shen W, Liu R, Hao J J Transl Int Med. 2024; 12(4):395-405.
PMID: 39360161 PMC: 11444470. DOI: 10.2478/jtim-2023-0130.
Zhang Y, Zhang J, Zhao S, Xu Y, Huang Y, Liu S Theranostics. 2024; 14(12):4787-4805.
PMID: 39239507 PMC: 11373622. DOI: 10.7150/thno.99112.